IPO Revance Therapeutics Inc. (RVNC) is a clinical stage specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products. Revance owns the worldwide rights to both product candidates.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment